Gensia Pharmaceuticals Inc. said Friday that its wholly ownedsubsidiary, Gensia Laboratories Ltd., has received abbreviatednew drug application approvals from the Food and DrugAdministration for intravenous gentamicin in two dosagestrengths.
Gentamicin is a broad spectrum antibiotic for treating infectionsassociated with sepsis and Staphylococcus aureus.
Gensia Laboratories, which manufactures generic injectabledrugs, now has 12 approved ANDAs covering eight ANDAproducts.
Shares of San Diego-based Gensia (NASDAQ:GNSA) rose 50 centson Friday to $37.
(c) 1997 American Health Consultants. All rights reserved.